comparative study of two brands of heparin already on the market

Conditions: Coronary Artery Bypass Grafting

Summary: two heparin brands have been in the market in canada for several years. heparin leo from leo pharma and hepalean from organon. the former is standardized by b.p (british pharmacopeia) while the latter is standardized by u.s.p (united states pharmacopeia). previous studies have shown heparin leo to have roughly a 10% less efficacy then hepalean. it has also been demonstrated that more protamine is required to reverse heparin leo. it is the investigators' intention to study the post-operative effects of the two brands of heparin and whether one of the two causes less bleeding after bypass surgery.

the study protocol attempts not to change the normal protocol for cardiac surgery too much. the two different brands of heparin-heparin leo (leo pharma) and hepalean (organon) are randomized by the float perfusionist using the program research randomizer.a 50 ml syringe is loaded with heparin for the anesthesiologist and labelled. a 20 ml syringe is loaded with heparin and thenn labelled. it is a double blinded trial with the surgeon and anesthetist not knowing which brand heparin is being used. all cases are isolated coronary artery bypass grafting (c.a.b.g) with no concomittant conditions. the following are the patients excluded from the trial 1. re-do 2. combination procedure 3. valve repair/replacement 4. iabp-pre/intra//post-op 5. cell saver intra-op 6. anemia (70 g/l)/bleeding disorder eg:jehovah's witness,hemophilia etc. 7. use of aprotinin 8. small adult \< 50 kg 9. aortic surgery with/without circ arrest 10. emergent patient with heart failure heparin will be administered in the trial to elevate the a.c.t-activated clotting time to 480 s and above and the heparin level to 300u/kg to intiate cardio-pulmonary bypass (c.p.b). additional heparin will be given to maintain the above-mentioned levels. the following data will be studied * bsa * height * weight * diagnosis * procedure * surgeon * anesthetist * perfusionist pre pump hb pump hb post pump hb pre pump act pump act post pump act projected heparin conc. slope protocol heparin conc heparin time cpb time x-clamp time heparin (initial dose) extra heparin on pump prime volume rap volume pump balance ml urine output ml average temp on cpb phenylephrine amt levofed amt creatinine ast calculated protamine dose at the end of the case extra protamine given total protamine cbc after pump total chest tube drainage in or ml total patient in or time pre pump post pump platelet inr ptt pt date time na plavix stopped asa stopped heparin stopped coumadin stopped ffp given total packed cells given total platelets given other factors given other blood product given ca2+ given ddavp given post-op 6 hrs 12 hrs 24 hrs chest tube drainage (ml) chest tube removed time hct platelet inr ptt additions packed cells cryo platelets other blood product / factors chest reopening yes no the reason if yes patient transfer date- time overall we are going to look at whether their is any impact on post-operative bleeding,hospital and icu stay.

Eligibility criteria:
inclusion criteria: * isolated coronary artery bypass surgery * normal hematocrit * normal creatinine * normal liver function exclusion criteria: * re-do * combination procedure * valve repair/replacement * iabp-pre/intra/post-op * cell saver intra-op * anemia (70 g/l)/bleeding disorder, e.g.,: jehovah's witness, hemophilia etc. * use of aprotinin * small adult \< 50 kg * aortic surgery with/without circ. arrest * emergent patient with heart failure

Keywords: heparin leo hepalean cpb cardiopuilmonary bypass cabg coronary artery bypass grafting anticoagulation efficacy